Filing Details
- Accession Number:
- 0001415889-22-003958
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-04-08 16:30:27
- Reporting Period:
- 2022-04-07
- Accepted Time:
- 2022-04-08 16:30:27
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1082554 | United Therapeutics Corp | UTHR | Pharmaceutical Preparations (2834) | 521984749 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1231589 | A Paul Mahon | C/O United Therapeutics Corporation 1040 Spring Street Silver Spring MD 20910 | Evp & General Counsel | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-04-07 | 6,000 | $111.00 | 42,487 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2022-04-07 | 2,914 | $184.93 | 39,573 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-04-07 | 1,886 | $185.79 | 37,687 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2022-04-07 | 1,200 | $186.50 | 36,487 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options | Disposition | 2022-04-07 | 6,000 | $0.00 | 6,000 | $111.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 46,552 | 2021-03-15 | 2028-03-15 | No | 4 | M | Direct |
Footnotes
- This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
- This transaction was executed in multiple trades at prices ranging from $184.31 to $185.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $185.33 to $186.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed in multiple trades at prices ranging from $186.40 to $186.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- These performance-based stock options were initially awarded on March 15, 2018, subject to a three-year performance condition tied to average cash profits during 2018-2020, and vested on March 15, 2021.
Billionaire Hedge Funds
